DiamiR Biosciences Partnered for Alzheimer's Study

Niki BioSolutions will conduct APOE genotyping for the Global Alzheimer's Platform Foundation's Bio-Hermes-002 study.

Updated on Oct. 14, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a test tube in navy and cream, representing advanced Alzheimer's genetic research methodology. — DiamiR Biosciences has partnered with the Global Alzheimer's Platform Foundation to conduct APOE genotyping using plasma samples for the Bio-Hermes-002 observational study. AI Illustration. Upload story photo >

Live Poll

Is it better for medical researchers to prioritize analyzing existing biological data over collecting new samples?

Niki BioSolutions subsidiary DiamiR Biosciences has partnered with the Global Alzheimer's Platform Foundation to provide APOE genotyping for the Bio-Hermes-002 observational study. The project uses plasma-based testing to determine genetic risk factors for Alzheimer's disease without additional blood draws.

Why it matters

Determining APOE status from existing plasma samples improves clinical trial design and helps researchers assess the risk of amyloid-related imaging abnormalities. This approach maximizes the utility of collected data while simplifying the logistical requirements for participants in Alzheimer's research.

DiamiR Biosciences uses a New York State-approved assay to determine APOE ε4 allele status, which serves as a genetic risk factor for late-onset Alzheimer's. The Bio-Hermes-002 study utilizes this data alongside amyloid PET imaging and cognitive assessments.

The players

DiamiR Biosciences

This is a subsidiary of Niki BioSolutions that specializes in diagnostic assays and maintains facilities in Princeton, New Jersey, and New Haven, Connecticut.

Global Alzheimer's Platform Foundation

This is a non-profit organization that coordinates a network of 75 clinical research sites worldwide to accelerate Alzheimer's disease treatments.

The details

Researchers will analyze banked plasma samples from the Bio-Hermes-002 study, which tracks participants ranging from those with normal cognition to those with mild Alzheimer's disease. Integrating this genetic information into the study dataset provides a comprehensive view of patient biomarkers and clinical outcomes.

Niki BioSolutions announced the partnership on October 14, 2026.

Health Landscape

This integration follows a broader industry shift toward maximizing the value of existing clinical research datasets through advanced genetic analysis. By adding APOE genotyping to the Bio-Hermes-002 study, researchers are moving toward a more holistic integration of genetic and digital biomarkers in Alzheimer's monitoring.

This development benefits participants in the Bio-Hermes-002 study by allowing for comprehensive genetic risk assessment without the need for additional blood draws. It also enhances the quality of data available to researchers who are developing future screening protocols for Alzheimer's patients.

The takeaway

Using banked samples for genetic testing saves study participants from repeated medical procedures while advancing critical Alzheimer's research. This method proves that integrating new diagnostic layers into ongoing observational trials is a highly efficient way to study complex neurodegenerative diseases.